Shield Bio
ClosedBringing 3rd generation, nanopore sequencing to healthcare to solve…
- Headquarters
- San Jose, California
- Employees
- 11–50
- Website
- shieldbio.com
- Last Round
- SeedJun 2016
- Rounds
- 1
About
Shield Bio is a precision medicine company with a proprietary platform that enables reliable nanopore sequencing in under a minute, in a clinical setting. It is focused on bringing 3rd generation or "nanopore" sequencing into clinical use to deliver on the promise of precision medicine. Shield is initially using the technology to improve the treatment of infectious disease and address the unmet clinical need of sepsis, which kills 300,000 people a year in the US alone.
Summary
Shield Bio is a Genomics company based in San Jose, United States. Its most recent funding was a Seed round in Jun 2016. Investors include Y Combinator Continuity Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2016
Investors
Similar Companies
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Healthcare cost management company providing data analytics and network-based payment solutions t...